Abstract:Objective To investigate the expression and prognostic role of heparan sulfate in human brain glioma. Methods The expression of heparan sulfate was determined by immunohistochemical technique in 171 tissue microarray samples of glioma. And relationship between the expression of heparan sulfate and clinicopathological characteristics of glioma patients was measured. The prognostic factors of 171 glioma patients were analyzed by Kaplan-Meier analysis and Cox proportional hazards regression analysis. Results The positive staining of heparan sulfate was localized in tumor cells and vascular endothelial cells in glioma. The heparan sulfate expression in vascular endothelial cells rather than tumor cells was observed to be different among patients with various grades of glioma (vascular endothelial cells, P < 0.05; tumor cells, P > 0.05). Furthermore, there was no significant difference in the survival time among patients with distinct expression level of heparan sulfate in tumor cells (P > 0.05). However, glioma patients with higher heparan sulfate expression in vascular endothelial cells had shorter overall survival (P < 0.05). Besides, Cox proportional hazards regression analysis demonstrated that high expression level of heparan sulfate in vascular endothelial cells of glioma tissue [Hl ^ R = 1.767 (95% CI: 1.009, 3.093)] and high-grade glioma [Hl ^ R = 6.702 (95% CI: 4.335, 10.312)] were factors impacting the suvival time of glioma patients. Conclusions The higher were the expression of heparan sulfate in vascular endothelial cells of glioma tissue and the grade of the tumor, the shorter was the overall survival in glioma patients.